Clinical Trials Browser

zimberelimab × Gastrointestinal × 90 days × Clear all

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04104672 2026-03-31

ARC-8

Phase 1 Active not recruiting

196 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05891171 2026-03-31

ARC-25

Phase 1 Active not recruiting

40 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05329766 2026-03-30

EDGE-Gastric

Phase 2 Active not recruiting

332 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05419479 2026-02-24

Switch Maintenance in Pancreatic

Phase 1/2 Suspended

46 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Phase 2 Recruiting

33 enrolled

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

Clinical Trials

STAR-221

ARC-8

ARC-25

EDGE-Gastric

Switch Maintenance in Pancreatic

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)